Treatment of palmoplantar pustulosis with arotinoid ethylester

European Journal of Dermatology

Volumn 19, Issue 5, 2009, Pages 474-477

  Shan, Shi Jun ^a   Li, Yuan Hong ^a   Zhang, Guowei ^b   Xiao, Ting ^a   Li, Changping ^c   Wei, Huachen ^d   Chen, Hong Duo ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Arotinoid ethylester; Palmoplantar pustulosis; Treatment

Indexed keywords

4 [2 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL) 1 PROPENYL]BENZOIC ACID ETHYL ESTER; GEMFIBROZIL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; HAIR LOSS; HUMAN; HYPERTRIGLYCERIDEMIA; INSOMNIA; MALE; PRURITUS; PUSTULE; PUSTULOSIS PALMOPLANTARIS; RELAPSE; SIDE EFFECT; SKIN EXFOLIATION; SKIN FISSURE; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; XEROSIS;

ADULT; BENZOATES; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RETINOIDS;

EID: 69849113302     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2009.0727     Document Type: Article

References (15)

1. Chalmers R. Management of palmoplantar pustulosis. Clin Exp Dermatol 2002; 27: 328-329
2. Burden AD, Kemmett D. The spectrum of nail involvement in palmoplantar pustulosis. Br J Dermatol 1996; 134: 1079-1082 (Pubitemid 26183141)
3. Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol 2007; 25: 510-518
4. William DJ, Berger TG, Elston DM. Andrews' Diseases of the Skin Clinical Dermatology. Pa: WB Saunders Co, 2006.
5. Bikowski JB. Psoriatic nail disease: Diagnosis and treatment options. Cutis 1999; 64: 1-9.
6. Orfanos CE, Ehlert R, Gollnick H. The retinoids. A review of their clinical pharmacology and therapeutic use. Drugs 1987; 34: 459-503.
7. Erkko P, Granlund H, Remitz A, et al. Double-blind placebocontrolled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis. Br J Dermatol 1998; 139: 997-1104. (Pubitemid 29010536)
8. Ettler K, Richards B, Kralove H, et al. Acitretin therapy for palmoplantar pustulosis combined with UVA and topical 8-MOP. Int J Dermatol 2001; 40: 539-544 (Pubitemid 33026318)
9. Van de Kerkhof PC. Pustulosis palmaris et plantaris. J Eur Acad Dermatol Venereol 2000; 14: 248.
10. Lassus A, Geiger JM. Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial. Br J Dermatol 1988; 119: 755-759 (Pubitemid 19002627)
11. Li YH, Gao XH, He CD, et al. Detection of human papillomavirus and response to oral arotinoid ethylester in 2 patients of Darier disease. Arch Dermatol 2002; 138: 695-696
12. Hoting E, Meissner K. Arotinoid-ethylester. Effectiveness in refractory cutaneous T-cell lymphoma. Cancer 1988; 62: 1044-1048
13. Mérot Y, Camenzind M, Geiger JM, et al. Arotinoid ethyl ester (Ro 13-6298): a long term pilot study in various dermatoses. Acta Derm Venereol 1987; 67: 237-242 (Pubitemid 17084986)
14. Fritsch PO. Retinoids in psoriasis and disorders of keratinization. J Am Acad Dermatol 1992; 27: 8-14.
15. Zimmermann B, Tsambaos D, Stürje H. Teratogenicity of arotinoid ethyl ester (RO 13-6298) in mice. Teratog Carcinog Mutagen 1985; 5: 415-431 (Pubitemid 16168964)